Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SELLAS Life Sciences Group Inc
SLS | US
1.19
USD-0.07
-5.56%
SLS | US
About SELLAS Life Sciences Group Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.19
Open
1.25
High
1.26
Low
1.18
SELLAS Life Sciences Group Inc. a late-stage clinical biopharmaceutical company focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS) a cancer immunotherapeutic agent that targets Wilms tumor 1 which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co. Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai) Inc. for the development and commercialization of GFH009 a highly selective small molecule CDK9 inhibitor currently under Phase 1 clinical trials. The company is headquartered in New York New York.
View LessSLS | US
Risk
42.6
Sharpe
-0.04
Luna's Score
33/100
Recommendation
Sell
Luna says (SLS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
47.9%1 month
42.6%3 months
47.8%6 months
64.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
27.83
Debt to equity
0.24
Debt to assets
0.05
Ent. to EBITDA
-1.71
Ent. to rev.
20.84
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
76.56M
MarketCap(USD)
76.56M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-82.50
Ret. on equity
-888.06
Short ratio
17.25
Short perc.
12.74
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.18
Range1M
0.24
Range3M
0.39
Volumes: Market Activity
Rel. volume
1.59
Price X volume
1.01M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.71 | - | Cheaper |
| Ent. to Revenue | 20.84 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 27.83 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 47.82 | - | Lower Risk |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 76.56M | - | Emerging |
